Charles Schwab’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $71.6M | Buy |
583,774
+30,818
| +6% | +$3.22M | 0.01% | 998 |
|
|
2026
Q1 | $58.3M | Sell |
552,956
-3,806
| -0.7% | -$337K | 0.01% | 1053 |
|
|
2025
Q4 | $48.6M | Buy |
556,762
+3,885
| +0.7% | +$318K | 0.01% | 1177 |
|
|
2025
Q3 | $36.7M | Sell |
552,877
-22,487
| -4% | -$1.28M | 0.01% | 1353 |
|
|
2025
Q2 | $31.8M | Buy |
575,364
+17,646
| +3% | +$847K | 0.01% | 1398 |
|
|
2025
Q1 | $27M | Sell |
557,718
-20,691
| -4% | -$867K | 0.01% | 1457 |
|
|
2024
Q4 | $22.3M | Buy |
578,409
+12,906
| +2% | +$563K | ﹤0.01% | 1638 |
|
|
2024
Q3 | $25.4M | Buy |
565,503
+39,850
| +8% | +$1.61M | ﹤0.01% | 1560 |
|
|
2024
Q2 | $18.2M | Buy |
525,653
+29,091
| +6% | +$852K | ﹤0.01% | 1739 |
|
|
2024
Q1 | $14.4M | Buy |
496,562
+41,241
| +9% | +$1.12M | ﹤0.01% | 1800 |
|
|
2023
Q4 | $10.4M | Buy |
455,321
+16,219
| +4% | +$284K | ﹤0.01% | 1959 |
|
|
2023
Q3 | $7.32M | Buy |
439,102
+19,492
| +5% | +$378K | ﹤0.01% | 2080 |
|
|
2023
Q2 | $11.6M | Buy |
419,610
+58,452
| +16% | +$1.46M | ﹤0.01% | 1846 |
|
|
2023
Q1 | $8.31M | Buy |
361,158
+21,137
| +6% | +$355K | ﹤0.01% | 1961 |
|
|
2022
Q4 | $3.71M | Buy |
340,021
+6,378
| +2% | +$53.8K | ﹤0.01% | 2358 |
|
|
2022
Q3 | $2.81M | Buy |
333,643
+8,885
| +3% | +$84.1K | ﹤0.01% | 2480 |
|
|
2022
Q2 | $2.57M | Sell |
324,758
-501
| -0.2% | -$6.06K | ﹤0.01% | 2485 |
|
|
2022
Q1 | $7.7M | Buy |
325,259
+8,080
| +3% | +$228K | ﹤0.01% | 2079 |
|
|
2021
Q4 | $10.8M | Buy |
317,179
+7,347
| +2% | +$232K | ﹤0.01% | 1960 |
|
|
2021
Q3 | $5.49M | Buy |
309,832
+28,454
| +10% | +$1.21M | ﹤0.01% | 2332 |
|
|
2021
Q2 | $12.6M | Buy |
281,378
+19,791
| +8% | +$653K | ﹤0.01% | 1880 |
|
|
2021
Q1 | $6.78M | Buy |
261,587
+36,367
| +16% | +$920K | ﹤0.01% | 2151 |
|
|
2020
Q4 | $4.54M | Buy |
225,220
+8,734
| +4% | +$188K | ﹤0.01% | 2266 |
|
|
2020
Q3 | $4.23M | Buy |
216,486
+159,414
| +279% | +$2.99M | ﹤0.01% | 2147 |
|
|
2020
Q2 | $1.01M | Buy |
57,072
+13,168
| +30% | +$165K | ﹤0.01% | 2625 |
|
|
2020
Q1 | $310K | Buy |
43,904
+151
| +0.3% | +$1.13K | ﹤0.01% | 2884 |
|
|
2019
Q4 | $309K | Buy |
43,753
+3,139
| +8% | +$31.2K | ﹤0.01% | 2965 |
|
|
2019
Q3 | $488K | Buy |
40,614
+4,145
| +11% | +$52.2K | ﹤0.01% | 2812 |
|
|
2019
Q2 | $442K | Buy |
+36,469
| New | +$403K | ﹤0.01% | 2866 |
|
|
2018
Q2 | – | Sell |
-32,315
| Closed | -$278K | – | 3141 |
|
|
2018
Q1 | $278K | Buy |
32,315
+13,015
| +67% | +$245K | ﹤0.01% | 2900 |
|
|
2017
Q4 | $402K | Buy |
19,300
+6,100
| +46% | +$108K | ﹤0.01% | 2783 |
|
|
2017
Q3 | $234K | Hold |
13,200
| – | – | ﹤0.01% | 2967 |
|
|
2017
Q2 | $150K | Hold |
13,200
| – | – | ﹤0.01% | 3069 |
|
|
2017
Q1 | $170K | Hold |
13,200
| – | – | ﹤0.01% | 2956 |
|
|
2016
Q4 | $291K | Buy |
+13,200
| New | +$294K | ﹤0.01% | 2859 |
|
Other funds holding PTGX
FCM
RI
JJ
Charles Schwab's PTGX Position: Q2 2026 in Review
Charles Schwab increased its Protagonist Therapeutics (PTGX) stake by 5.6% in Q2 2026, buying an estimated $3.22M and bringing the position to 583,774 shares worth $71.6M. The position accounts for 0.01% of the portfolio, ranked #998.
Charles Schwab first reported a position in PTGX in Q4 2016 and has held it in 35 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.
- Charles Schwab held 583,774 shares of Protagonist Therapeutics worth $71.6M as of Q2 2026.
- Charles Schwab bought 30,818 Protagonist Therapeutics shares in Q2 2026, an estimated $3.22M.
- Protagonist Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #998 holding.
- Charles Schwab first reported a position in Protagonist Therapeutics in Q4 2016 and has held it in 35 quarters since.
- 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.